Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 7/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | JUN | P05412 | 4/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633503 | 0.92 | MAPK10 (0.47) | MAPK10FGFR2JUNMAPK8MEN1 | |
| SCHEMBL1634397 | 0.92 | MAPK10 (0.59) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1631565 | 0.91 | MAPK10 (0.48) | MAPK10FGFR2JUNMAP3K11JAK2 | |
| SCHEMBL1633364 | 0.90 | KDR (0.45) | MAPK10FGFR2JUNMAP3K11CDK1 | |
| SCHEMBL13498285 | 0.89 | MAPK10 (0.47) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1634143 | 0.89 | MAPK10 (0.45) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1632955 | 0.89 | MAPK10 (0.47) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1631175 | 0.89 | FGFR2 (0.45) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1634203 | 0.89 | MAPK10 (0.48) | MAPK10FGFR2JUNMAPK8MAP3K11 | |
| SCHEMBL1632441 | 0.89 | MAPK10 (0.48) | MAPK10FGFR2JUNMAPK8JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885FGFR2 2062/4885ACHE 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.